Residential Psych denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for residential psych are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies Residential Psychiatric Treatment as "Not FDA-Approved"

Applying a "not FDA-approved" denial basis to residential psychiatric treatment is a category error. FDA approval applies to drugs, biologics, and certain medical devices — not to levels of care or treatment settings. Residential psychiatric treatment is a clinically defined, guideline-recognized care setting, not a product requiring FDA clearance. When UHC issues this denial, it typically reflects an automated claims-processing error, a miscoded claim, or the system misidentifying a specific therapeutic approach used within the program. The denial is almost always overturned on appeal.

## Why This Denial Is Appealable

There is no legal or regulatory framework under which a residential psychiatric care setting requires FDA approval, and UHC's own published medical policies do not assert one. The applicable coverage standard is medical necessity, not FDA approval. Appealing this denial requires demonstrating both the category error and the underlying medical necessity. The Mental Health Parity and Addiction Equity Act (MHPAEA) also provides a strong parallel argument: UHC does not apply an FDA-approval requirement to analogous medical levels of care (such as skilled nursing or inpatient rehabilitation), and it cannot apply one to mental health residential care.

## Federal Appeal Framework

• Clarification request: Request in writing that UHC identify the specific clinical policy and the specific service it determined requires FDA approval, and explain the regulatory basis for that requirement.
• Internal appeal (ACA §2719 / ERISA §503): File a written internal appeal within the deadline on your EOB. Argue both the category error and the medical necessity of the admission.
• Peer-to-peer review: Request a clinical peer-to-peer conversation between UHC's reviewer and the treating psychiatrist to resolve the classification issue quickly.
• External review: If internal appeal fails, independent external review is available within approximately four months of exhausting internal remedies. An IRO will apply objective clinical criteria and is unlikely to sustain this denial basis.
• Expedited review: Available if the patient is currently in residential treatment.

## Documentation to Gather

1. Facility licensure and accreditation: Documentation that the residential facility is licensed by the applicable state authority and, where applicable, accredited by the Joint Commission, CARF, or an equivalent body. 2. Service description: A description of the specific services provided confirming these are standard psychiatric and therapeutic services, not unapproved interventions. 3. Diagnosis and medical necessity: Current psychiatric diagnosis, clinical severity, and treating clinician documentation supporting residential placement. 4. Guideline reference: Reference to applicable national professional organization guidelines (APA, SAMHSA) recognizing residential psychiatric care as a standard level of care. 5. Prescriber medical-necessity letter: Letter from the treating psychiatrist confirming the treatment is standard of care and addressing the inapplicability of the FDA-approval standard.

## Criteria-Mapping Structure

Pull UHC's published medical policy for residential psychiatric care. Note that it will describe medical-necessity criteria, not FDA-approval criteria. Map the clinical documentation against those medical-necessity criteria in a side-by-side table. In a separate section, address the FDA-approval denial basis directly: state that no FDA-approval standard applies to this service category, cite UHC's own policy language, and invoke MHPAEA parity. Submit both sections together as your appeal response.